Quote:

---

Somebody help me out with this question- how difficult is it to ramp up and mass produce a stem-cell product and make it widely available on a scale of multi-millions of patients?

---

That's precisely what I have been spending my morning doing. However, I don't yet have the answer. With my limited knowledge, I have to assume it won't be accomplished on the scale of having Samsung Biologics produce 1-3M vials per month.

Let's also take a moment to acknowledge that MESO is an Australian company. Don't get me wrong, I fully accept that viable solutions may come from around the world, and those solutions might not be available to the US first. Hence, Trump wanting to buy that German vaccine company.

As I've mentioned, I don't view this as a horse race -- with the first horse to cross the finish line being the binary winner of the contest. There will be other horses to cross that finish line, and even the ones in the back of the field might have something valuable to offer -- not the least of which might be available inventory to throw at this global problem.